Benralizumab 30 mg SC + Mometasone Furoate + Matching placebo SC + Mometasone Furoate
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nasal Polyposis
Conditions
Nasal Polyposis
Trial Timeline
Jan 15, 2018 → Jul 31, 2020
NCT ID
NCT03401229About Benralizumab 30 mg SC + Mometasone Furoate + Matching placebo SC + Mometasone Furoate
Benralizumab 30 mg SC + Mometasone Furoate + Matching placebo SC + Mometasone Furoate is a phase 3 stage product being developed by AstraZeneca for Nasal Polyposis. The current trial status is completed. This product is registered under clinical trial identifier NCT03401229. Target conditions include Nasal Polyposis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03401229 | Phase 3 | Completed |
Competing Products
20 competing products in Nasal Polyposis